Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.299
Neutral
RSI(14)
57.644
Neutral
STOCH(KDJ)(9,3,3)
59.232
Buy
ATR(14)
1.641
Low Volatility
CCI(14)
37.000
Neutral
Williams %R
54.059
Neutral
TRIX(12,20)
0.549
Sell
StochRSI(14)
25.482
Sell
Search
GH Research PLC
GHRSAdd to Watchlist
28.070USD
-0.310-1.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.92BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.09%
5 Days
+2.90%
1 Month
+6.25%
6 Months
+79.25%
Year to Date
+121.02%
1 Year
+104.29%
Key Figures
28.500Open
28.850High
178.27KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.29%Turnover Ratio
28.380Prev. Close
27.860Low
4.08MTurnover
LossP/E Static
6.61P/B
0.00%Div Yield TTM
-18.94%ROA
24.66052wk High
0.69Volume Ratio
-38.96MNet Profit
62.05MShares
-0.9100EPS TTM
1.29Beta
-19.67%ROE
10.96052wk Low
3.49%Amplitude
--Gross Margin
1.92BMarket Cap
1.94Reward/Risk
4.36%Risk Rate
GH Research PLC News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
11
analysts
Buy
Current Rating
39.100
Target Price
+39.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
GH Research PLC
GHRS
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
28.028
Buy
MA10
27.951
Buy
MA20
27.500
Buy
MA50
24.934
Buy
MA100
21.279
Buy
MA200
17.939
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GH Research PLC Info
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Ticker SymbolGHRS
CompanyGH Research PLC
CEOValcheva (Velichka)
Website
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52697.700
+319.700 (+0.61%)
28480.500
+319.600 (+1.14%)
7525.500
+50.400 (+0.67%)
14787.000
+38.000 (+0.26%)
63213.000
+361.000 (+0.57%)
6399.500
+34.100 (+0.54%)
79.052
-6.882 (-8.01%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4074.550
+33.120 (+0.82%)
FAQs
What is the current price of GH Research PLC (GHRS)?
The current price of GH Research PLC (GHRS) is 28.07.
What is the symbol of GH Research PLC?
The ticker symbol of GH Research PLC is GHRS.
What is the 52-week high of GH Research PLC?
The 52-week high of GH Research PLC is 24.66.
What is the 52-week low of GH Research PLC?
The 52-week low of GH Research PLC is 10.96.
What is the market capitalization of GH Research PLC?
The market capitalization of GH Research PLC is 1.74B.
Is GH Research PLC (GHRS) currently rated as Buy, Hold, or Sell?
According to analysts, GH Research PLC (GHRS) has an overall rating of Buy, with a price target of 39.10.
What is the Earnings Per Share (EPS TTM) of GH Research PLC (GHRS)?
The Earnings Per Share (EPS TTM) of GH Research PLC (GHRS) is -0.79.